North Carolina biotech Kinvard Bio launched on Monday with a mission to develop next-generation drugs that can combat rising “superbugs.” Antimicrobial resistance (AMR) is one of the World Health Organization’s top public health concerns globally, claiming nearly 5 million lives per year. Kinvard’s launch on Monday was backed by the venture investment firm Kineticos Life Sciences, while much of the scientific groundwork done at Harvard was supported by the Blavatnik Biomedical Accelerator and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Small Harvard Start-Up Launches to Fight Huge Problem of Antimicrobial Resistance
Learn More
Discover the cutting-edge science we fund
Providing many of the world's best researchers, scientists, and universities with support, and funding to discover breakthroughs that solve humankind's greatest challenges.
See how we support great cultural institutions around the world
The Foundation contributes to renowned institutions that showcase the breadth of arts and culture, including performance, exhibition and education.
Visit the Blavatnik Archive
The Blavatnik Archive is a nonprofit foundation dedicated to preserving and disseminating materials that contribute to the study of 20th-century Jewish and world history, with a special emphasis on World War I, World War II, and Soviet Russia.
